In a nutshell This phase 2 clinical trial will test the safety and effectiveness of an ibrutinib (Imbruvica) and fludarabine (Fludara) treatment in patients with previously untreated chronic lymphocytic leukemia (CLL). The primary outcome will be measured by the safety and effectiveness of the treatment. The details Ibrutinib is a drug that...
Read MorePerformance status -0 – Asymptomatic Posts on Medivizor
Searching for newly diagnosed patients with B-lineage acute lymphoblastic leukemia to participate in a randomized immunotherapy trial
In a nutshell This phase 3 clinical trial will test the effectiveness of blinatumomab (Blincyto) with chemotherapy versus chemotherapy alone in treating patients with newly diagnosed B lineage acute lymphoblastic leukemia (ALL) that is BCR-ABL negative. The primary outcome will be measured by the overall survival. The details Blinatumomab is...
Read MoreSearching for patients with relapsed or refractory acute myeloid leukemia to test an immunotherapy
In a nutshell This phase 1 clinical trial will test the safety and effectiveness of AMV564 in treating relapsed or refractory (unresponsive to treatment) acute myeloid leukemia (AML). The primary outcome will be measured by adverse (negative) side effects and remission rate. The study is being conducted in Saint Louis, Missouri, New York City, and...
Read MoreLooking for patients with untreated mantle cell lymphoma to test the effectiveness of a combination therapy including acalabrutinib
In a nutshell This phase 3 clinical trial will test the effectiveness of acalabrutinib (ACP-196) with rituximab (Rituxan) and bendamustine (Treanda) in treating patients with previously untreated mantle cell lymphoma. The primary outcome will be measured by the time until the disease progresses. The details Acalabrutinib is an investigational...
Read MoreLatest guidelines relating to the treatment of the nodular lymphocyte predominant Hodgkin lymphoma.
In a nutshell This review provided guidelines relating to the treatment of nodular lymphocytic-predominant Hodgkin lymphoma (NLPHL). The authors concluded that appropriate treatment varied by age, disease-stage and the presence of relapse. Some background NLPHL is the rarer form of HL. It is characterized by the presence of atypical white...
Read MoreComparing chemotherapy regimens for advanced Hodgkin lymphoma
In a nutshell This study compared three chemotherapy combinations, standard dose BEACOPP, increased dose BEACOPP, and COPP-ABVD, for advanced Hodgkin lymphoma. The authors concluded that increased-dose BEACOPP was more effective. Some background The standard chemotherapies for advanced Hodgkin lymphoma (stage III or IV or those with additional...
Read More
